Top Markets
Coin of the day
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
주식 순위 #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
주가
$0.051239
마지막 동기화: 2025-11-24
시가총액
$1.38M
변동 (1일)
-4.48%
변동 (1년)
-54.57%
국가
NO
거래 BerGenBio ASA (BGBIO)

카테고리

BerGenBio ASA (BGBIO)의 배당 수익률 기록
BerGenBio ASA (주식 심볼: BGBIO)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
BerGenBio ASA (BGBIO)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 수익률 (TTM)